Try our Advanced Search for more refined results
Life Sciences
-
January 21, 2026
Fla. Dispensary Exposed Patient Data Via Google, Suit Says
A Florida man is suing a dispensary website in federal court, alleging it has violated federal health confidentiality laws by using Google Analytics Pixel on its website, which he said intercepts and collects private information for use in advertising.
-
January 20, 2026
Justices To Clarify What's Fair Game With 'Skinny Labels'
A new U.S. Supreme Court patent case that will require the justices to spell out what generic-drug makers can say when marketing drugs with so-called skinny labels will shape whether and how those companies use the tactic of carving out patented uses from labels, attorneys say.
-
January 20, 2026
Orrick Expands IP Team With Cadwalader, Kirkland Litigators
Orrick Herrington & Sutcliffe LLP has beefed up its intellectual property litigation team with three new partners experienced in counseling technology and life sciences clients, adding two former Cadwalader Wickersham & Taft LLP litigators in New York and a former Kirkland & Ellis LLP partner in Los Angeles.
-
January 20, 2026
Dentsply Can't Shed Investors' Aligner Injury Cover-Up Suit
Dental supply company Dentsply Sirona Inc. must face a proposed investor class action alleging it covered up medical injuries and other issues affecting an aligner business it acquired for $1 billion, and caused shareholder losses when the injuries were revealed and the acquisition collapsed.
-
January 20, 2026
Law360 Names Firms Of The Year
Eight law firms have earned spots as Law360's Firms of the Year, with 48 Practice Group of the Year awards among them, achieving milestones such as high-profile litigation wins at the U.S. Supreme Court and 11-figure merger deals.
-
January 20, 2026
Fed. Circ. Revives Inventor's Spinal Patent Case Against DePuy
The Federal Circuit on Tuesday revived an inventor's patent infringement suit against DePuy Synthes Cos., ruling that the persuasiveness of expert testimony that was excluded by a lower court is best left for the jury.
-
January 20, 2026
Philips CPAP Cancer Suit Sent Back To Kentucky
A Pennsylvania federal judge has sent back to state court a suit in the multidistrict litigation over recalled CPAP devices brought against Philips RS North America by a Kentucky woman who claims her sleep apnea machine caused her cancer, finding that a middleman supplier wasn't added to thwart federal jurisdiction.
-
January 20, 2026
NY Judge Orders SD To Pause Action Against Abortion Ads
A New York federal judge has temporarily barred South Dakota officials from taking action against an abortion rights group that launched an advertising campaign in the state promoting its website, which explains how to order abortion medication online.
-
January 20, 2026
Ex-Med Spa Workers Say Poaching Claims Can't Stay In Conn.
Two former Connecticut medical spa workers have asked a judge to dismiss claims they lured clients and a colleague to a nearby competitor, saying their employment agreements select Delaware as the necessary forum and venue for any dispute.
-
January 20, 2026
Johnson & Johnson Faces 2nd Talc Trial In Philadelphia
Counsel for a woman who died of ovarian cancer told a Philadelphia jury Tuesday that her condition was caused by her decades-long use of asbestos-laced talc in Johnson & Johnson's flagship baby powder and that the company kept pushing the product in the market despite knowing about its health risks.
-
January 20, 2026
Va. Lawmakers Eye Psilocybin Regulation Pending FDA Action
Virginia lawmakers have introduced legislation directing state regulators to develop rules governing the prescription, possession and use of medical psilocybin, the active compound in psychoactive mushrooms, in the event that it receives approval from the U.S. Food and Drug Administration.
-
January 20, 2026
CorMedix Investors Seek First OK Of Governance Reform Deal
Investors in CorMedix Inc. have told a New Jersey federal judge that company directors have agreed to implement several corporate governance reforms to resolve a consolidated shareholder derivative lawsuit accusing the executives of making misleading statements about delays in the regulatory approval of the company's lead drug candidate.
-
January 20, 2026
McCarter & English Knocks Down Biotech Malpractice Appeal
A New Jersey appellate court on Tuesday upheld the dismissal of a biotech company's malpractice and related claims against McCarter & English LLP, finding the biotech company was required to bring those allegations during the firm's earlier suit to recover more than $837,000 in unpaid legal fees.
-
January 20, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court wrapped up last week with a mix of deal litigation, governance fights and disclosure battles, including a proposed settlement over a contested medical device sale, a merits dismissal tied to a $2 billion biotech exit and dueling lawsuits over Paramount Skydance's pursuit of Warner Bros. Discovery.
-
January 16, 2026
Law360 Names Practice Groups Of The Year
Law360 would like to congratulate the winners of its Practice Groups of the Year awards for 2025, which honor the attorney teams behind litigation wins and significant transaction work that resonated throughout the legal industry this past year.
-
January 16, 2026
DOJ Reports Historic $6.8B False Claims Act Haul In 2025
The U.S. Department of Justice secured more than $6.8 billion via settlements and judgments under the False Claims Act in the fiscal year that ended September 2025, the largest amount recovered in a single year in the history of the FCA, the DOJ said Friday.
-
January 16, 2026
PBMs Seek Exit From Philly's Suit Over Opioid Crisis
CVS Health Corp. and other pharmacy benefit managers asked a Pennsylvania federal judge to let them out of the city of Philadelphia's lawsuit claiming they contributed to the opioid epidemic in the city, arguing that the city waited too long to file its suit and lacked standing to sue the companies.
-
January 16, 2026
SEC Fines Biopharma Co. Execs Over Hidden FDA Findings
Former executives of Spero Therapeutics will pay over $187,000 to settle the U.S. Securities and Exchange Commission's claims they downplayed the likelihood that the U.S. Food and Drug Administration would reject the biopharmaceutical company's new drug application in 2022, the commission said on Friday.
-
January 16, 2026
Lifecore Investors Ink $3.8M Deal In Accounting Controls Suit
Biotech company Lifecore Biomedical Inc. has reached a $3.8 million deal with its investors to end their claims the company had weak controls over its financial reporting, impairing its ability to remain compliant with Nasdaq listing requirements and causing share declines.
-
January 16, 2026
6th Circ. Revives Biomed Co. Investor's Suit Over Stock Sale
The Sixth Circuit has ruled that a man who sold his stock in a biomedical research company just before being told the company planned to pursue private equity financing can bring his breach of contract and fiduciary duty claims, reversing a lower court's ruling granting summary judgment to the biomedical company.
-
January 16, 2026
NuVasive Loses Appeal Over Ex-Exec's Ties To Competitor
The Delaware Supreme Court on Friday affirmed the dismissal of NuVasive Inc.'s long-running lawsuit accusing a former top executive of breaching fiduciary duties and contractual obligations while planning to move to a rival spine-surgery company, ending nearly a decade of litigation over alleged conflicts and disloyal conduct.
-
January 16, 2026
Acadia Investors Get Initial OK For $179M Settlement
Acadia Healthcare Co. Inc. investors have received the first OK from a Tennessee federal judge for a $179 million settlement in a class action alleging the company misled them about the strength of its U.K. operations.
-
January 16, 2026
Pomerantz To Lead Biohaven Investors' FDA Approval Suit
Pomerantz LLP will lead a proposed class of investors accusing biopharmaceutical company Biohaven Ltd. of overstating the odds that two of its product candidates would receive regulatory approval, a Connecticut judge said Friday.
-
January 16, 2026
Taxation With Representation: Stibbe, A&O Shearman, Latham
In this week's Taxation With Representation, Keurig Dr Pepper Inc. plans to complete its deal to snap up coffee company JDE Peet's NV, Boston Scientific Corp. acquires medical device company Penumbra Inc., and fitness and wellness platform parent Playlist merges with fitness technology company EGYM.
-
January 16, 2026
J&J Largely Loses Bid To Toss Former Atty's NJ Bias Suit
A New Jersey federal judge largely shot down Johnson & Johnson's bid to scrap a former company data privacy attorney's racial and gender discrimination suit and rejected its bid to sanction her over the case.
Expert Analysis
-
Fed. Circ. In August: A Framework For AIA Derivation Disputes
In Global Health Solutions v. Selner, the Federal Circuit established how to assess derivation challenges under the America Invents Act's first-to-file system, making it easier for petitioners to determine a challenge's odds of success, say attorneys at Knobbe Martens.
-
USPTO's Track One A Reliable Patent Pathway Amid Backlog
As the U.S. Patent and Trademark Office faces a backlog of unexamined utility, plant and reissue patent applications, patent applicants should consider utilizing the USPTO's Track One Program, which not only expedites the process but also increases the likelihood of working with more senior examiners, says Ryan Schermerhorn at Marshall Gerstein.
-
Vanda Ruling Opens Door For Contesting FDA Drug Denials
The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.
-
Series
Law School's Missed Lessons: Mastering Time Management
Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.
-
Rare Del. Oversight Ruling Sends Governance Wake-Up Call
An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.
-
How Hyperlinks Are Changing E-Discovery Responsibilities
A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.
-
Pharma Copay Programs Raise Complex Economic Questions
The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.
-
State False Claims Acts Can Help Curb Opioid Fund Fraud
State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.
-
Beaming Up Lessons From William Shatner's Failed Patent Bid
In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.
-
The Pros And Cons Of Levying Value-Based Fees On Patents
The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.
-
Series
Writing Musicals Makes Me A Better Lawyer
My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.
-
Between The Lines Of EPO's Adoption Of Color Drawings
The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.
-
What Prop 65 Ruling Means For Cosmetics, Personal Care Biz
A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.
-
Series
Adapting To Private Practice: From Va. AUSA To Mid-Law
Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.
-
2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls
Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.